EA200400241A1 - Направленные к мишени мультимерные контрастные вещества, основанные на пептидах - Google Patents
Направленные к мишени мультимерные контрастные вещества, основанные на пептидахInfo
- Publication number
- EA200400241A1 EA200400241A1 EA200400241A EA200400241A EA200400241A1 EA 200400241 A1 EA200400241 A1 EA 200400241A1 EA 200400241 A EA200400241 A EA 200400241A EA 200400241 A EA200400241 A EA 200400241A EA 200400241 A1 EA200400241 A1 EA 200400241A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- target
- directed
- multimeral
- substances based
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 239000002872 contrast media Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Abstract
Описаны пептиды и основанные на пептидах направленные к мишени мультимерные контрастные вещества, а также способы получения и применения контрастных веществ.Отчет о международном поиске был опубликован 2003.05.22.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30872101P | 2001-07-30 | 2001-07-30 | |
PCT/US2002/024261 WO2003011115A2 (en) | 2001-07-30 | 2002-07-30 | Peptide-based multimeric targeted contrast agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200400241A1 true EA200400241A1 (ru) | 2004-06-24 |
EA006239B1 EA006239B1 (ru) | 2005-10-27 |
Family
ID=23195121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400241A EA006239B1 (ru) | 2001-07-30 | 2002-07-30 | Направленные к мишени мультимерные контрастные вещества, основанные на пептидах |
Country Status (23)
Country | Link |
---|---|
US (5) | US6991775B2 (ru) |
EP (1) | EP1420681B1 (ru) |
JP (2) | JP4298501B2 (ru) |
KR (2) | KR20040020074A (ru) |
CN (1) | CN1599577A (ru) |
AR (1) | AR036196A1 (ru) |
AU (1) | AU2002318931B2 (ru) |
BR (1) | BR0211623A (ru) |
CA (1) | CA2455638C (ru) |
CO (1) | CO5560528A2 (ru) |
EA (1) | EA006239B1 (ru) |
EC (1) | ECSP044996A (ru) |
HU (1) | HUP0402029A3 (ru) |
IL (1) | IL160001A0 (ru) |
MX (1) | MXPA04000967A (ru) |
NO (1) | NO20040402L (ru) |
NZ (1) | NZ531338A (ru) |
PL (1) | PL368807A1 (ru) |
TW (2) | TWI284539B (ru) |
UA (2) | UA84432C2 (ru) |
WO (1) | WO2003011115A2 (ru) |
YU (1) | YU9404A (ru) |
ZA (1) | ZA200401606B (ru) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI284539B (en) * | 2001-07-30 | 2007-08-01 | Epix Pharm Inc | A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide |
US20060148683A1 (en) * | 2001-10-16 | 2006-07-06 | Mcmurry Thomas J | Detection and treatment of intravascular lesions |
AR047692A1 (es) * | 2003-07-10 | 2006-02-08 | Epix Medical Inc | Imagenes de blancos estacionarios |
DE102004038134B4 (de) | 2004-08-05 | 2013-07-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
JP2008508333A (ja) * | 2004-08-05 | 2008-03-21 | ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン | 標的分子の改変および組織化のための多価キレーター |
US20060275217A1 (en) * | 2005-05-06 | 2006-12-07 | Caravan Peter D | Chemical exchange saturation transfer contrast agents |
JP4559922B2 (ja) * | 2005-06-21 | 2010-10-13 | 株式会社東芝 | 蛍光性錯体及びそれを用いた照明装置 |
WO2007009058A2 (en) | 2005-07-13 | 2007-01-18 | Georgia State University Research Foundation, Inc. | Contrast agents and methods for preparing contrast agents |
KR100703593B1 (ko) * | 2005-08-08 | 2007-04-06 | 경북대학교 산학협력단 | Dtpa-비스(피콜린아미드)리간드,이를 포함하는가돌리늄 착물 및 이들의 제조 방법 |
JP5377965B2 (ja) | 2005-09-09 | 2013-12-25 | ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド | 標的化された造影剤および造影剤を標的化するための方法 |
CA2621763C (en) * | 2005-09-09 | 2021-04-06 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
WO2007042504A2 (fr) | 2005-10-07 | 2007-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
EP1933884B1 (en) * | 2005-10-11 | 2017-09-06 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
EP1955071A4 (en) | 2005-10-28 | 2009-03-18 | Invitrogen Corp | ASSAYS OF ACTIVITY KINASE AND UBIQUITINATION |
FI20055653A (fi) | 2005-12-08 | 2007-06-09 | Wallac Oy | Leimausreagenssi |
WO2007073792A1 (de) * | 2005-12-19 | 2007-07-05 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur herstellung von 4,4-diphenylcyclohexanol |
US20080058636A1 (en) * | 2005-12-29 | 2008-03-06 | Epix Pharmaceuticals, Inc. | Methods of myocardial imaging |
WO2008019123A2 (en) | 2006-08-04 | 2008-02-14 | Georgia State University Research Foundation, Inc. | Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity |
US8420327B2 (en) * | 2006-12-14 | 2013-04-16 | Georgia State University Research Foundation | Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity |
US9814672B2 (en) * | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
FR2914303A1 (fr) | 2007-03-28 | 2008-10-03 | Guerbet Sa | Composes pour le diagnostic de l'apoptose. |
FR2914304B1 (fr) | 2007-03-28 | 2012-11-16 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de vcam. |
MX2010007501A (es) | 2008-01-08 | 2010-08-16 | Lantheus Medical Imaging Inc | Conjugados de n-alcoxiamida como agentes formadores de imagen. |
US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
US20090236541A1 (en) * | 2008-03-24 | 2009-09-24 | General Electric Company | System and Methods for Optical Imaging |
WO2009146099A2 (en) | 2008-04-02 | 2009-12-03 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
US9074014B2 (en) | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
EP2915538A3 (en) * | 2008-08-07 | 2015-10-14 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
AU2009280021B2 (en) * | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
CN102170895A (zh) * | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | 葡萄糖依赖性促胰岛素多肽类似物 |
WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
WO2010054321A2 (en) | 2008-11-07 | 2010-05-14 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
US8864821B2 (en) | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
CN102356087A (zh) | 2009-03-19 | 2012-02-15 | 惠氏有限责任公司 | [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法 |
WO2010121133A2 (en) * | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
US20120107248A1 (en) * | 2009-07-08 | 2012-05-03 | Mayo Foundation For Medical Education And Research | Imaging gastrointestinal volumes and motility |
JP5676600B2 (ja) | 2009-07-08 | 2015-02-25 | ランセウス メディカル イメージング, インコーポレイテッド | 造影剤としてのn−アルコキシアミド抱合体 |
CA2777682C (en) | 2009-10-13 | 2015-02-24 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
WO2011152782A1 (en) * | 2010-06-01 | 2011-12-08 | Ge Healthcare Bio-Sciences Ab | Novel chelator and use thereof |
FR2968562B1 (fr) | 2010-12-14 | 2013-01-11 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de muc5ac |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
US9011816B2 (en) * | 2011-03-25 | 2015-04-21 | Case Western Reserve University | Fibronectin targeting contrast agent |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
US9849201B2 (en) | 2013-05-03 | 2017-12-26 | Washington University | Homing agents |
US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
WO2015017815A1 (en) | 2013-08-01 | 2015-02-05 | Rochester Institute Of Technology | Modular imaging agents containing amino acids and peptides |
US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
US10471162B2 (en) | 2014-06-20 | 2019-11-12 | The General Hospital Corporation | Collagen targeted imaging probes |
US20180126013A1 (en) * | 2015-05-06 | 2018-05-10 | H.Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapeutic and companion imaging agents to target mc1r |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
WO2017004211A1 (en) | 2015-06-29 | 2017-01-05 | Collagen Medical, LLC | Collagen imaging compositions |
WO2017027834A1 (en) | 2015-08-13 | 2017-02-16 | The General Hospital Corporation | Manganese-based chelate conjugates for molecular mr imaging |
JP7034160B2 (ja) | 2016-11-28 | 2022-03-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物 |
CN106946926A (zh) * | 2017-02-27 | 2017-07-14 | 西北大学 | 一种具有多齿氨羧类二聚体螯合剂及其制备方法、应用和分离介质 |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
RU2019139434A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Моноклональные антитела против igf-1r и их применение |
CN111263747B (zh) | 2017-05-05 | 2023-10-27 | 探针技术开发及商业化中心 | 双官能螯合物的药代动力学增强及其用途 |
RU2681318C1 (ru) * | 2017-11-24 | 2019-03-06 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+ |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
US11944690B2 (en) | 2018-11-23 | 2024-04-02 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
CN111233714B (zh) * | 2020-03-18 | 2022-04-08 | 滨海吉尔多肽有限公司 | 一种maps多肽的制备方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5099069A (en) * | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5001230A (en) | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB9111199D0 (en) | 1991-05-23 | 1991-07-17 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5364613A (en) * | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US5641878A (en) | 1991-05-15 | 1997-06-24 | Diatron Corporation | Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding |
US5009069A (en) * | 1990-08-24 | 1991-04-23 | Molini Alberto E | Method of recovering energy from ocean water |
CA2104860A1 (en) * | 1991-03-08 | 1992-09-09 | Thomas T. Andersen | Endothelin antagonists |
WO1993017719A1 (en) | 1992-03-13 | 1993-09-16 | Diatech, Inc. | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION |
US5637759A (en) * | 1992-07-30 | 1997-06-10 | The Regents Of The University Of California | Metal-ligating amino acid derivatives for MRI and for peptide synthesis |
DE69526203T2 (de) | 1994-01-12 | 2002-11-28 | Amersham Plc Little Chalfont | Biologische zielgerichtete mittel |
US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
EP0769958B1 (en) | 1994-07-11 | 2003-04-16 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
TW319763B (ru) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
GB9502065D0 (en) | 1995-02-02 | 1995-03-22 | Nycomed Imaging As | Contrast media |
AU5752696A (en) | 1995-05-18 | 1996-11-29 | Regents Of The University Of Michigan, The | Dna binding antibodies |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
DE19539409C2 (de) | 1995-10-11 | 1999-02-18 | Diagnostikforschung Inst | Kontrastmittel für die Nahinfrarot-Diagnostik |
DK0857216T3 (en) | 1995-10-17 | 2014-12-15 | Ab Enzymes Oy | Cellulases, GENES ENCODING THEM AND USES THEREOF |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
IT1291623B1 (it) * | 1997-04-18 | 1999-01-11 | Bracco Spa | Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici |
US6342598B1 (en) * | 1998-11-26 | 2002-01-29 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
AU768859B2 (en) * | 1999-07-29 | 2004-01-08 | Dyax Corp. | Binding moieties for fibrin |
CZ2002343A3 (cs) | 1999-07-29 | 2002-08-14 | Epix Medical, Inc. | Cílená multimerní zobrazovací činidla s multilokální vazebnou schopností |
WO2001025410A2 (en) | 1999-10-01 | 2001-04-12 | Angstrom Pharmaceuticals, Inc. | DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
WO2001030398A2 (en) | 1999-10-22 | 2001-05-03 | Insight Neuroimaging Systems, Llc | Ligand chelated paramagnetic mri contrast agents |
EP1251876A2 (en) * | 2000-01-22 | 2002-10-30 | Epix Medical, Inc. | Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6517814B2 (en) * | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
TWI284539B (en) * | 2001-07-30 | 2007-08-01 | Epix Pharm Inc | A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide |
-
2002
- 2002-07-29 TW TW093136632A patent/TWI284539B/zh not_active IP Right Cessation
- 2002-07-29 TW TW091116938A patent/TWI240632B/zh active
- 2002-07-30 CN CNA028192559A patent/CN1599577A/zh active Pending
- 2002-07-30 PL PL02368807A patent/PL368807A1/xx not_active Application Discontinuation
- 2002-07-30 KR KR10-2004-7001314A patent/KR20040020074A/ko active IP Right Grant
- 2002-07-30 KR KR1020087026503A patent/KR20080100856A/ko active IP Right Grant
- 2002-07-30 UA UAA200601920A patent/UA84432C2/ru unknown
- 2002-07-30 YU YU9404A patent/YU9404A/sh unknown
- 2002-07-30 UA UA2004010709A patent/UA81226C2/uk unknown
- 2002-07-30 AU AU2002318931A patent/AU2002318931B2/en not_active Ceased
- 2002-07-30 EA EA200400241A patent/EA006239B1/ru not_active IP Right Cessation
- 2002-07-30 MX MXPA04000967A patent/MXPA04000967A/es unknown
- 2002-07-30 US US10/209,172 patent/US6991775B2/en not_active Expired - Lifetime
- 2002-07-30 WO PCT/US2002/024261 patent/WO2003011115A2/en active Application Filing
- 2002-07-30 IL IL16000102A patent/IL160001A0/xx unknown
- 2002-07-30 HU HU0402029A patent/HUP0402029A3/hu unknown
- 2002-07-30 BR BR0211623-5A patent/BR0211623A/pt not_active IP Right Cessation
- 2002-07-30 JP JP2003516355A patent/JP4298501B2/ja not_active Expired - Fee Related
- 2002-07-30 EP EP02750374.7A patent/EP1420681B1/en not_active Expired - Lifetime
- 2002-07-30 AR ARP020102880A patent/AR036196A1/es unknown
- 2002-07-30 US US10/209,183 patent/US20030180222A1/en not_active Abandoned
- 2002-07-30 CA CA2455638A patent/CA2455638C/en not_active Expired - Lifetime
- 2002-07-30 NZ NZ531338A patent/NZ531338A/en not_active IP Right Cessation
-
2004
- 2004-01-29 NO NO20040402A patent/NO20040402L/no not_active Application Discontinuation
- 2004-02-20 CO CO04015097A patent/CO5560528A2/es not_active Application Discontinuation
- 2004-02-25 US US10/786,791 patent/US7238341B2/en not_active Expired - Lifetime
- 2004-02-26 ZA ZA200401606A patent/ZA200401606B/en unknown
- 2004-02-27 EC EC2004004996A patent/ECSP044996A/es unknown
-
2005
- 2005-04-04 US US11/098,665 patent/US7927581B2/en active Active
- 2005-07-27 JP JP2005218096A patent/JP2005314438A/ja active Pending
-
2006
- 2006-11-29 US US11/564,648 patent/US20070185311A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400241A1 (ru) | Направленные к мишени мультимерные контрастные вещества, основанные на пептидах | |
EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
EA200000920A1 (ru) | Производные бициклических гидроксамовых кислот | |
EA199900381A1 (ru) | Арил(тио)эфиры галогенпиримидина в качестве пестицидов | |
EA200300873A1 (ru) | Новая соль сукцинат o-десметилвенлафаксина | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
EA200201214A1 (ru) | Замещенные тиоацетамиды | |
EA200901129A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
EA200000310A1 (ru) | April - новый белок, воздействующий на рост | |
EA200100053A1 (ru) | Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат | |
DE60144145D1 (de) | Subtilisin-variante | |
DE69435105D1 (de) | Derivate therapeutischer Peptide | |
DE60330376D1 (de) | Defructosylierungsverfahren | |
EA200100012A1 (ru) | Мостиковые инденопирролокарбазолы | |
EA199901013A1 (ru) | Гели пролонгированного действия | |
EA200501250A1 (ru) | Композиция, содержащая смесь активных начал, и способ ее получения | |
EA200300450A1 (ru) | Фармацевтические растворы соединений модафинила | |
IL145689A0 (en) | Methods | |
EA200501046A1 (ru) | Эсциталопрамгидробромид и способ его получения | |
EA199900235A1 (ru) | Аморфные бензотиофены, способы получения и способы применения | |
DE60039049D1 (de) | Erhöhte expression von proteinen mittels gfp | |
ATE356207T1 (de) | Humanes btrcp protein | |
EA200400392A1 (ru) | Связывающий каспазу-8 белок, его получение и применение | |
EA200200798A1 (ru) | Кальцилитические соединения | |
ES2185652T3 (es) | Oligopeptidos derivados de fragmentos de proteinas c-reactiva. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in name of a patent proprietor in a eurasian patent |
Designated state(s): AM AZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |